» Articles » PMID: 1976661

Tolerance to Intravenous Nitroglycerin in Patients with Congestive Heart Failure: Role of Increased Intravascular Volume, Neurohumoral Activation and Lack of Prevention with N-acetylcysteine

Overview
Date 1990 Oct 1
PMID 1976661
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

To better understand the mechanism of nitrate tolerance in patients with congestive heart failure, 13 patients received a 24 h infusion of nitroglycerin (1.5 micrograms/kg body weight per min) with or without N-acetylcysteine (225 mg/kg per 24 h). The infusions were separated by a 24 h nitrate-free interval. By the end of the nitroglycerin infusion, mean arterial pressure had returned to baseline values and there was a significant increase in ventricular filling pressures and systemic vascular resistance compared with values after 1 h of treatment. The simultaneous infusion of N-acetylcysteine had no effect on these changes. Although a strict fluid restriction of 1.5 liters/day was maintained for 1 week before and throughout the study, after 24 h of nitroglycerin infusion there was a significant and similar degree of hemodilution whether nitroglycerin was infused alone (9.1 +/- 4.3%) or with N-acetylcysteine (8.7 +/- 4.1%). This hemodilution corresponded to an increase in intravascular volume of 745 +/- 382 ml, most of which occurred during the 1st h. Plasma renin activity increased and plasma atrial natriuretic peptide decreased during the infusion. The results of this study suggest that nitrate tolerance is multifactorial. In addition to the previously described pharmacologic tolerance to the effect of nitroglycerin on vascular smooth muscle, a capillary fluid shift from the extravascular to intravascular space appears to be involved, especially during the 1st h of the infusion. A third mechanism, reflex neurohumoral activation, also seems to contribute to the genesis of nitroglycerin tolerance.

Citing Articles

Nicardipine versus nitroglycerin for hypertensive acute heart failure syndrome: a single-center observational study.

Koroki T, Abe T, Ochiai H J Rural Med. 2022; 17(1):33-39.

PMID: 35047100 PMC: 8753259. DOI: 10.2185/jrm.2021-045.


Acute effects of sublingual nitroglycerin on cardiovagal and sympathetic baroreflex sensitivity.

Hamaoka T, Blaha C, Luck J, Leuenberger U, Sinoway L, Cui J Am J Physiol Regul Integr Comp Physiol. 2021; 321(4):R525-R536.

PMID: 34378422 PMC: 8560367. DOI: 10.1152/ajpregu.00304.2020.


KSHF Guidelines for the Management of Acute Heart Failure: Part II. Treatment of Acute Heart Failure.

Lee J, Kim M, Yoo B, Park S, Park J, Shin M Korean Circ J. 2019; 49(1):22-45.

PMID: 30637994 PMC: 6331324. DOI: 10.4070/kcj.2018.0349.


The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.

Divakaran S, Loscalzo J J Am Coll Cardiol. 2017; 70(19):2393-2410.

PMID: 29096811 PMC: 5687289. DOI: 10.1016/j.jacc.2017.09.1064.


Nitrates as a Treatment of Acute Heart Failure.

Alzahri M, Rohra A, Peacock W Card Fail Rev. 2017; 2(1):51-55.

PMID: 28785453 PMC: 5490950. DOI: 10.15420/cfr.2016:3:3.